Abstract
Purpose
The advent of hybrid positron emission tomography/magnetic resonance (PET/MR) systems has opened the gate to integrated multiparametric evaluation of patients with suspected cardiac sarcoidosis. The aim of the present paper is to systematically review all available literature to define the role of hybrid PET/MR in patients with confirmed or suspected cardiac sarcoidosis.
Methods
The review strategy was developed following the PRISMA 2009 statement. An electronic database (Medline, Google Scholar, Clinical Trials.gov) search was conducted to identify articles on hybrid PET/MR in cardiac sarcoidosis. Only reports on hybrid PET/MR systems were considered. All PET tracers were considered. No date limitation was applied. Following duplicate removal, abstracts or full articles in case of case reports were screened for inclusion criteria. The full text of the remaining studies was reviewed.
Results
Eleven studies were found, including seven case reports, two case series, and two diagnostic accuracy studies. All studies reported feasibility and interpretability of cardiac 18F-FDG PET/MR in cardiac sarcoidosis. The two case series demonstrated non-inferiority of PET/MR compared to PET/CT and, in fact, suggested greater sensitivity. Diagnostic accuracy studies showed satisfactory sensitivity and specificity of PET/MR to diagnose cardiac sarcoidosis. Two reports also showed the usefulness of cardiac PET/MR to assess response to treatment.
Conclusion
Hybrid cardiac PET/MR is a valuable tool for the diagnosis of cardiac sarcoidosis. Moreover, as it offers activity and tissue characterisation, it can be used to tailor and monitor treatment.
Similar content being viewed by others
References
Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153–2165
Birnie DH, Nery PB, Ha AC, Beanlands RSB (2016) Cardiac sarcoidosis. J Am Coll Cardiol 68:411–421
Silverman KJ, Hutchins GM, Bulkley BH (1978) Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58:1204–1211
Perry A, Vuitch F (1995) Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119:167–172
Terasaki F, Yoshinaga K (2017) New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol 3(1):42–45
Birnie DH, Sauer WH, Bogun F et al (2014) HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11:1305–1323
Ishimaru S, Tsu**o I, Takei T et al (2005) Focal up- take on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26:1538–1543
Blankstein R, Osborne M, Naya M et al (2014) Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 63:329–336
Joshi NV, Vesey AT, Williams MC et al (2014) 18F- fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 383:705–713
Ohira H, Tsu**o I, Ishimaru S et al (2008) Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35:933–941
Patel MR, Cawley PJ, Heitner JF et al (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120:1969–1977
Coleman GC, Shaw PW, Balfour PC et al (2017) Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic re- view and meta-analysis. J Am Coll Cardiol Imaging 10:411–420
Kawakatsu N, Suzuki A, Serizawa N et al (2016) Isolated cardiac sarcoidosis diagnosed by electroanatomic voltage map**-guided endomyocardial biopsy combined with magnetic resonance imaging and positron emission tomography. J Cardiol Cases 14(4):107–110
Bravo PE, Raghu G, Rosenthal DG et al (2017) Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol 241:457–462
Vita T, Okad D, Veillet-Chowdhury M et al (2018) Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 11:e007030
Schlosser T, Nensa F, Mahabadi AA et al (2013) Hybrid MRI/PET of the heart: a new complementary imaging technique for simultaneous acquisition of MRI and PET data. Heart 99:351–352
Nensa F, Poeppel TD, Beiderwellen K et al (2013) Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology 268:366–373
White J, Rajchl M, Butler J et al (2013) Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography–magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 127(22):e639–e641
Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG (2014) Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J 35(5):312
Nensa F, Tezgah E, Poeppel T, Nassenstein K, Schlosser T (2015) Diagnosis and treatment response evaluation of cardiac sarcoidosis using positron emission tomography/magnetic resonance imaging. Eur Heart J 36(9):550
Wada K, Niitsuma T, Yakami T et al (2016) Simultaneous cardiac imaging to detect inflammation and scar tissue with (18)F-fluorodeoxyglucose PET/MRI in cardiac sarcoidosis. J Nucl Cardiol 23(5):1180–1182
Abgral R, Dweck M, Trievieri MG et al (2017) Clinical utility of combined FDG-PET/MR to assess myocardial disease. JACC Cardiovasc Imaging 10(5):594–597
Kiko T, Masuda A, Nemoto A et al (2018) Cardiac sarcoidosis after glucocorticoid therapy evaluated by 18F-fluorodeoxyglucose PET/MRI. J Nucl Cardiol 25(2):685–687
Lee CH, Son JW, Kong EJ (2018) Cardiac sarcoidosis presenting as complete atrioventricular block: findings on PET/MRI. Korean Circ J 48(10):947–948
Hanneman K, Kadoch M, Guo H et al (2017) Initial experience with simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. Clin Nucl Med 42(7):e328–e334
Wisenberg G, Thiessen JD, Pavlovsky W, Butler J, Wilk B, Prato FS (2019) Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis. J Nucl Cardiol. https://doi.org/10.1007/s12350-018-01578-8 (Epub ahead of print)
Wicks E, Menezes LJ, Barnes A et al (2018) Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 19(7):757–767
Dweck MR, Abgral R, Trivieri MG et al (2018) Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 11(1):94–107
Robson P, Dey D, Newby DE, Berman D, Li D, Fayad ZA, Dweck MR (2017) MR/PET imaging of the cardiovascular system. JACC Cardiovasc Imaging 10:1166–1179
Nensa F, Poeppel TD, Beiderwellen K et al (2013) Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology 268:366–373
Brendle C, Schmidt H, Oergel A et al (2015) Segmentation-based attenuation correction in positron emission tomography/magnetic resonance: erroneous tissue identification and its impact on positron emission tomography interpretation. Investig Radiol 50:339–346 (United States)
Lapa C, Reiter T, Kircher M et al (2016) Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget 7:77807–77814
Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P (2016) A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res 6:52
Passah A, Kaushik P, Patel C, Parakh N (2018) Gallium-68 DOTANOC scan in a patient with suspected cardiac sarcoidosis. J Nucl Cardiol 25(6):2177–2178
Acknowledgement
NIH/NHLBI R01HL071021 funding.
Author information
Authors and Affiliations
Contributions
VV: content planning, literature search, literature review, writing, editing. FP: content planning, literature review, editing. BE: content planning, literature review, editing. MP: content planning, literature review, editing. MGT: literature review, editing. RP: literature review, editing. AR: literature review, editing. FZA: literature review, editing. LG: content planning, editing. PM: content planning, literature review, editing. CPG: content planning, literature review, editing.
Corresponding author
Ethics declarations
Conflict of interest
Vittoria Vergani, Ferro Paola, Busnardo Elena, Mapelli Paola, Trivieri Maria G, Robson Philip, Abrgral Ronan, Fayad Zahi A, Gianolli Luigi, Camici Paolo G declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
M Picchio received support for travel expenses for attending a meeting from GE Healthcare. GE Healthcare had no involvement in writing this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
M. Picchio is the co-last author.
Rights and permissions
About this article
Cite this article
Vergani, V., Busnardo, E., Mapelli, P. et al. Hybrid cardiac PET/MR: the value of multiparametric assessment in cardiac sarcoidosis. Clin Transl Imaging 7, 317–326 (2019). https://doi.org/10.1007/s40336-019-00345-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-019-00345-0